Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions.
Currently Mydecine Innovations Group encompasses three companies, each with its own unique vertical focus and core strengths that position it to be a market leader. Collectively these companies also act as an integrated entity that is greater than the sum of its parts, both in output and impact.
Mydecine Health Sciences (MHS) is a vertically integrated company developing novel functional© mushroom products and psychedelic medicines for healthy and vulnerable populations.
Mindleap is an advanced digital health platform that helps people connect with mental health specialists who can empower them to thrive and develop habits for a healthy mind.
NeuroPharm Inc. (NPI) is developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations.